By the ISCT Business Development & Finance Committee With investment activity fluctuating across the cell and gene therapy sector, access to timely financing and M&A insights is essential for organizations to stay informed and ahead of the curve. The ISCT Business Development &...
David Moolten, MD Medical Director American Red Cross United States Why the Quality and Make-up of Starting Material Matters The familiar truism garbage in, garbage out can be ruinously accurate in the setting of cell and gene therapy production. What is in the bag at the beginning...
Nathan Manley, PhD Senior Principal, Head of Nonclinical Dark Horse Consulting Group, Inc. United States Construction of an efficient, pressure-tested, development roadmap is an essential tool for preclinical cell and gene therapy (CGT) companies looking to obtain stakeholder buy-in and...
Tracy TreDenick, BA BTL Co-Founder, Head of Regulatory & Quality BioTech Logic Dark Horse Consulting Group Early-stage biopharma companies often face the same challenge: the need for quality oversight arises long before they are prepared to hire a full-time in-house QA team and/or at...
Joanna Niska-Blakie, PhD Global Product Manager Qiagen Poland Introduction Manufacturing therapeutics, especially viral vectors for cell and gene therapy, demands rigorous safety standards and strict regulatory compliance. Key challenges include efficient cell lysis and the thorough...
Gene therapy is reshaping how we approach genetic disorders, turning what was once considered untreatable into areas of possibility. With over 30 FDA-approved treatments and more than 2,000 therapies currently in development worldwide, the field is advancing at a remarkable pace. A key...
Q&A with AGC Biologics' Cell Process Development Manager, Sara Morlacchi, PhD Introduction In this Q&A, Sara Morlacchi from AGC Biologics provides her expert analysis on the current state of the cell therapy space, the growth of the industry, and barriers for cost and...
Innovation delivers promise, but infrastructure delivers impact. Cryoport Systems is Enabling the Outcome™, connecting innovation with infrastructure to unlock the future of advanced therapies. The life sciences are in the midst of a golden age of innovation. Advanced therapies such as...
Nicholas Ostrout, PhD ViroCell Biologics United States Farzin Farzaneh, PhD, CSO ViroCell Biologics United States Hilary Schultz, MS Persephoni Biosciences, LLC. United States Click Here to Read Article #IndustryMemberNews
Sheryl Brown-Lewis, BS American Red Cross United States Leading with Innovation and Reliability In cell and gene therapy, timing can make or break a process. Access to high-quality starting material that is ready when needed is not just helpful; it is essential. With decades of...